266 related articles for article (PubMed ID: 36756869)
1. A profile of the live biotherapeutic product RBX2660 and its role in preventing recurrent
Chopra T
Expert Rev Anti Infect Ther; 2023 Mar; 21(3):243-253. PubMed ID: 36756869
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
[TBL] [Abstract][Full Text] [Related]
3. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.
Orenstein R; Dubberke ER; Khanna S; Lee CH; Yoho D; Johnson S; Hecht G; DuPont HL; Gerding DN; Blount KF; Mische S; Harvey A
BMC Infect Dis; 2022 Mar; 22(1):245. PubMed ID: 35279084
[TBL] [Abstract][Full Text] [Related]
4. The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660.
Orenstein R
Infect Dis Ther; 2023 Jan; 12(1):1-7. PubMed ID: 36342653
[TBL] [Abstract][Full Text] [Related]
5. Microbiota restoration therapies for recurrent
DuPont HL; DuPont AW; Tillotson GS
Therap Adv Gastroenterol; 2024; 17():17562848241253089. PubMed ID: 38800353
[TBL] [Abstract][Full Text] [Related]
6. Microbiome therapeutics for the treatment of recurrent
Bloom PP; Young VB
Expert Opin Biol Ther; 2023 Jan; 23(1):89-101. PubMed ID: 36536532
[TBL] [Abstract][Full Text] [Related]
7. Update on microbiota-derived therapies for recurrent Clostridioides difficile infections.
Benech N; Barbut F; Fitzpatrick F; Krutova M; Davies K; Druart C; Cordaillat-Simmons M; Heritage J; Guery B; Kuijper E;
Clin Microbiol Infect; 2024 Apr; 30(4):462-468. PubMed ID: 38101472
[TBL] [Abstract][Full Text] [Related]
8. Fecal microbiota transplantation for treatment of patients with recurrent
Voth E; Khanna S
Expert Rev Anti Infect Ther; 2020 Jul; 18(7):669-676. PubMed ID: 32266848
[TBL] [Abstract][Full Text] [Related]
9. Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection.
Dubberke ER; Orenstein R; Khanna S; Guthmueller B; Lee C
Infect Dis Ther; 2023 Feb; 12(2):703-709. PubMed ID: 36544075
[TBL] [Abstract][Full Text] [Related]
10. SER-109 (VOWST
Blair HA
Drugs; 2024 Mar; 84(3):329-336. PubMed ID: 38441806
[TBL] [Abstract][Full Text] [Related]
11. RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections.
Khanna S; Pardi DS; Jones C; Shannon WD; Gonzalez C; Blount K
Clin Infect Dis; 2021 Oct; 73(7):e1613-e1620. PubMed ID: 32966574
[TBL] [Abstract][Full Text] [Related]
12. Advancements in Novel Live Biotherapeutic Products for Clostridioides difficile Infection Prevention.
Lavoie T; Appaneal HJ; LaPlante KL
Clin Infect Dis; 2023 Dec; 77(Suppl 6):S447-S454. PubMed ID: 38051964
[TBL] [Abstract][Full Text] [Related]
13. Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent
Tillotson G; Archbald-Pannone L; Johnson S; Ng S; Ando M; Harvey A; Bancke L; Feuerstadt P
Open Forum Infect Dis; 2023 Jan; 10(1):ofac703. PubMed ID: 36686631
[TBL] [Abstract][Full Text] [Related]
14. Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study.
Langdon A; Schwartz DJ; Bulow C; Sun X; Hink T; Reske KA; Jones C; Burnham CD; Dubberke ER; Dantas G;
Genome Med; 2021 Feb; 13(1):28. PubMed ID: 33593430
[TBL] [Abstract][Full Text] [Related]
15. Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day!
Khanna S
J Intern Med; 2021 Aug; 290(2):294-309. PubMed ID: 33856727
[TBL] [Abstract][Full Text] [Related]
16. Gut microbiota changes associated with
Gonzales-Luna AJ; Carlson TJ; Garey KW
Gut Microbes; 2023; 15(1):2223345. PubMed ID: 37318134
[TBL] [Abstract][Full Text] [Related]
17. Therapeutics for
Khanna S; Voth E
Expert Rev Gastroenterol Hepatol; 2023; 17(9):903-911. PubMed ID: 37606962
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA.
Lodise T; Guo A; Yang M; Cook EE; Song W; Yang D; Wang Q; Zhao A; Bochan M
Adv Ther; 2023 Jun; 40(6):2784-2800. PubMed ID: 37093359
[TBL] [Abstract][Full Text] [Related]
19. Live Biotherapeutic Products for the Prevention of Recurrent
Pettit NN; Shaeer KM; Chahine EB
Ann Pharmacother; 2024 Mar; ():10600280241239685. PubMed ID: 38546138
[TBL] [Abstract][Full Text] [Related]
20. Pediatric Fecal Microbiota Transplantation in Recurrent
Parnell JM; Nicholson MR; Kellermayer R; Kahn SA
Pediatr Ann; 2021 Dec; 50(12):e515-e521. PubMed ID: 34889135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
